Abivax SA Stock Soars Amid Promising Ulcerative Colitis Trial Results
On July 23, 2025, shares of Abivax SA, a French biotechnology company specializing in anti-viral therapies and therapeutic vaccines, experienced a dramatic surge following the release of positive clinical trial results for its ulcerative colitis drug, Obefazimod. The company’s stock price skyrocketed by over 500%, reflecting investor optimism about the drug’s potential.
Abivax SA, listed on the NYSE Euronext Paris, reported successful outcomes from its Phase 3 ABTECT-1 and ABTECT-2 clinical trials. The trials focused on Obefazimod, a first-in-class miR-124 enhancer designed to treat adult patients with moderately to severely active ulcerative colitis. The drug met its primary goals, leading to a significant increase in the company’s market valuation.
Several financial analysts and institutions responded to the trial results by upgrading their ratings and price targets for Abivax stock. Morgan Stanley upgraded the stock to “Overweight,” citing the strong data from the ulcerative colitis trials. Similarly, Leerink raised its price target to $74, while Guggenheim increased its target to $101. JMP Securities also adjusted its target to $95, reflecting the positive market sentiment.
The company’s market capitalization, which stood at approximately €551.57 million as of July 21, 2025, saw a substantial boost due to the stock’s performance. Despite a negative price-to-earnings ratio of -3.11, the promising trial results have shifted investor focus towards the potential revenue from Obefazimod.
Abivax SA, founded in 2013 and headquartered in Paris, France, continues to develop a range of therapeutic products, including ABX 464 for HIV/AIDS, ABX 203 for chronic hepatitis B, and ABX 196, an art immune enhancer. The company also has pre-clinical programs targeting diseases such as Dengue fever, Ebola, and Chikungunya.
The positive trial outcomes have positioned Abivax SA as a potentially disruptive player in the biotechnology sector, particularly in the treatment of inflammatory bowel disorders. Investors and industry observers are closely monitoring the company’s next steps, including potential regulatory submissions and commercialization strategies for Obefazimod.
For more information, visit Abivax’s official website at www.abivax.com .